帕博利珠单抗+阿昔替尼用于晚期肾细胞癌一线治疗后的治疗 - Suppr

Suppr

超能文献

Pembrolizumab + axitinib beyond first-line therapy for mRCC.

作者信息

Thomas Tim

机构信息

Nature Reviews Urology, .

出版信息

Nat Rev Urol. 2023 Mar;20(3):131. doi: 10.1038/s41585-023-00743-0.

DOI:10.1038/s41585-023-00743-0

PMID:36797430

Abstract

摘要

相似文献

Pembrolizumab + axitinib beyond first-line therapy for mRCC.

Nat Rev Urol. 2023 Mar;20(3):131. doi: 10.1038/s41585-023-00743-0.

Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.

Immunotherapy. 2020 Dec;12(17):1237-1246. doi: 10.2217/imt-2020-0034. Epub 2020 Sep 3.

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.

JAMA Netw Open. 2020 Oct 1;3(10):e2016144. doi: 10.1001/jamanetworkopen.2020.16144.

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.

Eur J Cancer. 2021 Mar;145:1-10. doi: 10.1016/j.ejca.2020.12.009. Epub 2021 Jan 4.

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.

J Med Econ. 2021 Jan-Dec;24(1):291-298. doi: 10.1080/13696998.2021.1883034.

Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.

Future Oncol. 2021 Jan;17(3):241-254. doi: 10.2217/fon-2020-0079. Epub 2020 Oct 5.

Axitinib-ICIs boost the RCC armamentarium.

Nat Rev Clin Oncol. 2019 Apr;16(4):207. doi: 10.1038/s41571-019-0193-5.

[First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].

Urologe A. 2017 Mar;56(3):385-386. doi: 10.1007/s00120-017-0335-2.

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Oncologist. 2021 Feb;26(2):e290-e297. doi: 10.1002/ONCO.13522. Epub 2020 Sep 28.

[Presurgical Treatment with Axitinib and Pembrolizumab Reduced Operation Risk by Downsizing the Vena Cava Tumor Thrombus in Clear Cell Renal Cell Carcinoma : A Case Report].

Hinyokika Kiyo. 2021 Oct;67(10):443-447. doi: 10.14989/ActaUrolJap_67_10_443.

本文引用的文献

Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer. 2023 Apr;21(2):221-229. doi: 10.1016/j.clgc.2023.01.002. Epub 2023 Jan 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pembrolizumab + axitinib beyond first-line therapy for mRCC.

作者信息

Thomas Tim

机构信息

Nature Reviews Urology, .

出版信息

Nat Rev Urol. 2023 Mar;20(3):131. doi: 10.1038/s41585-023-00743-0.

DOI:10.1038/s41585-023-00743-0

PMID:36797430

Abstract

摘要